Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A

Trial Profile

Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A

Suspended
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Beroctocog alfa (Primary) ; Moroctocog alfa
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GC Pharma
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 13 Oct 2016 Status changed from recruiting to suspended, according to a Green Cross media release.
    • 02 Jul 2014 Change in trial focus from PK to Safety.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top